An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Nasdaq3d
Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (NYSE ... a weight loss candidate in pill form. And Lilly may even submit orforglipron for regulatory approval as early as this year. If Lilly is able to ...
Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025?
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
Why the Obesity Drug Revolution Is a Work in Progress
Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
PSA: The 'Ozempic Dupes' Are Coming, and They Might Work Even Better
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...